Johnson & Johnson stock has been trading above both its 50-day and 200-day simple moving averages since mid-June, signaling positive momentum. The company's Innovative Medicine segment grew 6.2% organically in the first half of 2026, driven by drugs like Darzalex and new launches including Icotyde, which J&J believes has $10 billion in sales potential. However, MedTech growth slowed to 4.5% in the second quarter, partly due to a 2% decline in Abiomed sales following a U.K. clinical trial that raised questions about the Impella device. J&J also faces headwinds from Stelara's loss of exclusivity, which reduced Innovative Medicine growth by 7.6% in the second quarter, and a $5.5 billion talc litigation settlement agreed in July 2026. The stock has risen 26.5% this year and trades at 21.23 times forward earnings, above its five-year mean of 15.65, while the Zacks Consensus Estimate for 2027 earnings has edged up to $12.80 per share.
